PRB4

Across TCGA pan-cancer cohorts, PRB4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRB4 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PRB4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRB4 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, OV, and LUAD are the cancer types where PRB4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.111	0.730	<.001	42	view →
OV	DFS	Median	II,III,IV	0.182	0.541	.011	30	view →
LUAD	OS	Median	All	0.345	0.686	.010	6	view →
SKCM	DFS	Median	III,IV	0.882	0.575	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRB4–STAD (OS)

Open the STAD breakdown →